Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MY008211A in Healthy Volunteers
NCT05642585Phase 1Completed
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd.
- Start
- May 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MY-008 in paroxysmal nocturnal hemoglobinuria (PNH) (7 arms), sponsored by Wuhan Createrna Science and Technology Co., Ltd. Primary endpoint: Incidence and severity of adverse events up to 21 days. Started May 2022; status: completed.
02
Drugs
MY-008
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05642585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642585.